uniQure NV Receives a Buy from Cowen & Co.

By Carrie Williams

Cowen & Co. analyst Ritu Baral reiterated a Buy rating on uniQure NV (NASDAQ: QURE) yesterday. The company’s shares opened today at $5.60, close to its 52-week low of $4.72.

Baral noted:

“QURE reported 1Q17 financials and presented multiple updates at ASGCT recently.”

According to TipRanks.com, Baral is a 5-star analyst with an average return of 11.4% and a 46.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Protalix Biotherapeutics, and Intra-Cellular Therapies.

Currently, the analyst consensus on uniQure NV is Moderate Buy and the average price target is $12.50, representing a 123.2% upside.

In a report issued on May 16, Oppenheimer also reiterated a Buy rating on the stock with a $17 price target.

Based on uniQure NV’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $3.54 million and GAAP net loss of $21.61 million. In comparison, last year the company earned revenue of $4.3 million and had a GAAP net loss of $22.69 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, Netherlands.